肺癌组织中癌基因ras和c-myc蛋白产物的免疫组织化学研究

目的］探讨肺癌组织中癌基因ｒａｓ和ｃ ｍｙｃ蛋白产物Ｐ２１，Ｐ６２表达特征以及临床病理意义．［方法］应用免疫组织化学方法（Ｓ Ｐ法）检测６９例肺癌组织标本中Ｐ２１和Ｐ６２蛋白表达．［结果］Ｐ２１和Ｐ６２在肺癌中的阳性表达率分别为６８％，７１％；在肺癌癌旁支气管粘膜和腺体中的阳性表达率分别为１８％和２９％，与肿瘤区相比较差异非常显著．Ｐ２１和Ｐ６２蛋白之间的阳性率无统计学差异．６９例肺癌中２１例（３０％）同时有Ｐ２１和Ｐ６２共同表达．肺腺癌Ｐ２１蛋白表达高于肺鳞癌．Ｐ２１和Ｐ６２蛋白表达与肺癌病人性别、年龄、肿瘤分期及肺癌分化程度无关．［结论］ｒａｓ和ｃ ｍｙｃ癌基因突变是肺癌的早期事件，ｒａｓ和ｃ ｍｙｃ癌基因在肺癌发生发展中具有相同重要性

Immunohistochemical study on the ras and c myc oncogene protein products in lung cancer

Objective To find the expression feature and clinicopathological significance of the ras and c myc oncogene protein products in lung cancer.Method Immunohistochemical methods(S P method) were used to study the expression of P 21 and P 62 in 69 cases of lung cancer.Result The postive rate of P 21 and P 62 oncoproteins in lung cancer is 68% and 71% respectively; whereas that in tissues surrounding the cancer is 18% and 29% respectively. No Signficant difference is found between P 21 and P 62 oncoproteins expression in lung cancer.Co expression of the P 21 and P 62 oncoproteins are seen in 21 cases of lung cancer. No correlation are found between expression of P 21 ,P 62 and sex, age,differentiated or clinical tumor stage.Conclusion Mutations of the ras and c myc oncogenes are an early event in lung cancer.Both the ras and c myc oncogene have the same importance in the carcinogenesis and progression of lung cancer.